Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Motor Activity 3Colorectal Neoplasms 2Vomiting 1Urologic Neoplasms 1Urinary Incontinence 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Pain, Postoperative 1Ovarian Neoplasms 1Osteolysis 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Nausea 1Multiple Myeloma 1Lung Neoplasms 1Liver Diseases 1Liver Cirrhosis 1Jaw Cysts 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

AZD 6244 4trametinib 1mirdametinib 1Control Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neurofibroma, Plexiform × Control Groups × Clear all
NCT05913037 2025-03-06

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 3 Active not recruiting
167 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡